nGageIT Digital Health™

Exhaled breath analysis is

the new frontier of medical testing

Technology

Applications

Insights

About Us

Medication Adherence

nGageIT Digital Health™

Sensors that can detect the medication you take from your breath

Technology

Applications

Insights

About Us

nGageIT Digital Health™

Exhaled breath analysis is

the new frontier of medical testing

Technology

Applications

Insights

About Us

Medication Adherence

nGageIT Digital Health™

Portable, non-invasive, real-time medication adherence tracking sensors drive better outcomes

Technology

Applications

Insights

About Us

Intelligent Breath Sensor Technology

capable of significantly improving disease and diagnostic screening and testing, precision medicine, and medication adherence programs

nGageIT Digital Health™ is a breath diagnostics company pioneering new medical treatment breakthroughs. This starts with medication adherence, treatment verification and compliance, and progresses to patient wellness factors and biopatterns, precision medicine, and more advanced diagnostic applications.

AT THE POINT OF CARE

nGageIT Digital Health™ nanoparticle biosensors are revolutionary mobile point-of-care devices that are the size of a smart phone.

DIRECT BREATH TESTING

Our direct breath testing means there is no requirement for handling of pre-concentration or pre-processing of the exhaled breath samples.

REAL-TIME CLOUD PROCESSING

No processing or transportation time means results are processed against existing VOC libraries in the cloud, and delivered in near-real-time.

CLINICAL RESULTS IN MINUTES

Secure cloud-based digital lab processing power outputs test results to care providers and teams in minutes rather than days or weeks.

Intelligent nanosensors that are designed exclusively to map the human exhaled breath

Our sensors can enable the delivery of critical real-time adherence, wellness, and behavioral data, enabling the development of effective and efficient risk monitoring and management systems, interventions, improved adherence, and improved patient health and outcomes.
Learn how we can address specific market challenges
We deliver significant Ai-driven insights into patient behaviors and treatment results.
Learn more about how our Insights can drive patient outcomes

Medication non-adherence is an up-to USD $500 billion dollar problem in the United States annually

Chronic Conditions 50%
About one half of adults or 117 million have one chronic condition and almost one-third have two or more.
Medication Adherence 53%
Among chronic disease patients, approximately 50% do not take their medications as prescribed (one quarter are never even filled).
Treatment Compliance 32%
Nearly one-third of heart attack patients are not persistent with their prescribed medications by 6 months.

More than 80% of lung cancer patients will survive for at least a year if diagnosed at the earliest stage compared to around 15% for people diagnosed with the most advanced stage of disease.

Survival rates comparing stage 1 and stage 4 lung cancer

0%
Stage 1 The overall 5-year survival rate for stage 1A lung cancer is 49 percent and for 1B is 45 percent
0%
Stage 4 Less than 10% survival rate for diagosed Stage 4 cancers

The global clinical trials market is said to be expected to reach USD 65.2 billion by 2025.

The globalization of clinical trials (led by the emergence of CROs as a driving force in the clinical trials market), development of new treatments and evolving technologies such as personalized medicine and programs as well as digital monitoring services along with the increasing demand for data and analytics by way of CRO support all are said to play key roles in shaping the future of clinical trials.
However, the complexity of trials, patient recruitment, adoption of technology, regulatory requirements, high cost levels and many others issues 
create challenges conducting and working in the clinical trials market. High rates of failure resulting from lengthy and complex study designs and the constraints driven by the complexities of guidelines have resulted in all-time high clinical trials.  Additionally, patient access to appropriate clinical trials and engagement is declining, and staff and operations management is more challenging than ever.
The overall cost of failed clinical trails is extremely high, with estimates varying between $800 million and $1.4 billion USD.
0%
Percentage of Clinical Trials that Fail Due To Non-Adherence
0%
The standard estimates for overall probability of clinical succes http://blogs.sciencemag.org/pipeline/archives/2018/02/02/a-new-look-at-clinical-success-rates

We help patients, providers, physicians, practitioners, and health systems provide better treatment programs, more efficient treatment plans and diagnostics solutions, more timely interventions and urgent patient care, and more improved patient outcomes.

Our proprietary DIGITAL BREATH BIOMARKER™ processing engine revolutionizes the identification of health conditions
and diseases based on the analysis of the VOC data patterns in a subject’s exhaled breath.

News & Updates: